Clinical Trials for Deciphera Pharmaceuticals

Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Ripretinib (QINLOCK®) According to Current SmPC

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor